Bexson Biomedical is developing a non-opioid therapy for chronic and acute pain management based upon a unique formulation of ketamine for subcutaneous delivery. Ketamine is an anesthetic with powerful antidepressant and pain relieving properties. Bexson is developing a specific solution to the pharmacokinetic issues presented by this useful molecule, one that will allow exquisite control over dosing to achieve desired clinical effects across a range of disorders.  Bexson is developing a safe and effective low-dose ketamine strategy for use in the home environment, a game changer for difficult to treat pain conditions and neuropsychological conditions.

We've got a huge problem. 

Pain management is both a miracle and curse in modern medicine–it seems we can’t live with it and we can’t live without it. Every year up to 160,000 Americans become addicted to opioid medication even with appropriate standard of care delivery.2 All stakeholders in pain management agree that this is unacceptable, but solutions have been elusive.      

There is an answer. 

Ketamine and other NMDA receptor antagonists constitute massive untapped potential in everyday pain management. Specifically, ketamine has substantial established efficacy in pain management, and power that rivals even that of strong opioids. Approved for use in anesthesia in 1970, ketamine produces powerful analgesia, has a favorable safety profile and is physically non-addictive. But perhaps most important, ketamine specifically mitigates the processes that progress acute pain conditions to chronic pain nightmares.  

Ketamine has repeatedly been shown to help avert the development of hyperalgesia–a common process wherein appropriate pain in response to injury graduates to become its own life-destroying entity. While treating acute pain directly, ketamine also stops the development of chronic pain as well. Unfortunately, opioids produce exactly the opposite effect.    


Despite these amazing properties, ketamine is currently not available outside of the hospital or clinic due to pharmacokinetic and pharmacodynamic issues and side effects. Bexson plans to solve that problem.   


Bexson’s lead develop strategy is based upon a novel ketamine delivery system–one that includes formulation innovations tuned to a minimally invasive, wearable, subcutaneous infusion pump with anti-diversion properties. The safety and dosing control provided by our product will be a game changer in acute and chronic pain management. The United States and the world are desperately in need of powerful, yet non-addictive pain management solutions and Bexson Biomedical is striving to meet that need. 


In February 2019 Bexson was granted orphan status for ketamine in the treatment of Complex Regional Pain Syndrome by the FDA, our lead indication. In parallel, we are pursuing other orphan indications and large-market, acute and chronic pain conditions.